Please login to the form below

Not currently logged in
Email:
Password:

Dr Steven Gillis joins Shire’s board of directors

He will sit on the pharma firm's science and technology and its remuneration committee

Steven Gillis - ShireShire has appointed managing director of Arch Venture Partners Dr Steven Gillis to its board of directors.

Dr Gillis will join the Ireland-based pharma firm on October 1, becoming a member of its science and technology committee as well as its remuneration committee.

Commenting on his appointment, he said: “Shire has a clear and ambitious patient-focused vision for the future and I look forward to the opportunity to help them achieve it.”

A trained immunologist, Dr Gillis has experience in the life sciences industry through his work at Arch, which provides venture capital to firms working on new life sciences technologies.

Prior to this role, Dr Gillis was a founder and director of Corixa Corporation, which was acquired by GlaxoSmithKline in 2005 (GSK), and he was previously a founder and director of Immunex Corporation.

He currently holds a number of other roles, including as a non-executive director of New Zealand-based biotech Genesis Research and Development Corporation.

10th September 2012

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics